卡维地洛治疗原发性高血压300例的疗效

OBSERVATION ON EFFICACY OF CARVEDILOL IN TREATMENT OF 300 PATIENTS WITH ESSENTIAL HYPERTENSION

目的：评价卡维地洛对原发性高血压的临床疗效及安全性。方法：多中心开放试验， 用卡维地洛（ｃａｒｖｅｄｉｌｏｌ） 对３００ 例原发性高血压病患者进行为期４ 周的治疗，剂量为２０ ～４０ ｍ ｇ／ｄ 。结果：服药４ 周后，平均收缩压（ Ｓ Ｂ Ｐ） 及舒张压（ Ｄ Ｂ Ｐ） 分别下降２１ ．６ ｍ ｍ Ｈｇ 及１５ ．５ ｍ ｍ Ｈｇ 。临床总有效率为８７ ．３ ％ 。３００ 病例中，１９８ 例（６６ ％ ） 口服剂量为１０ ｍ ｇ ，ｂｉｄ ，另１０２ 例（３４ ％ ） 第３ 周起剂量增至２０ ｍｇ ，ｂｉｄ 。卡维地洛不良反应轻微，发生率为１８ ．３ ％ ，主要不良反应为头晕和嗜睡。卡维地洛对血糖、血脂、血电解质、肝肾功能等均无明显影响，心电图检查治疗前后也无明显变化。结论：卡维地洛治疗轻、中度高血压疗效确切，不良反应少，是一种安全有效的抗高血压药。

OBJECTIVE:To evaluate the clinical efficacy and safety of carvedilol in treatment of essential hypertension.METHODS:The multicenter,open trial was carried out in 300 patients with essential hypertension.They were treated with carvedilol in a daily dose of 20～40 mg for 4 weeks.RESULTS:The reduction in mean SBP and DBP were 21.6 mmHg and 15.5 mmHg respectively after 4 weeks of treatment with a total effective rate of 87.3% and a incidence of ADRs of 18.7%.The major ADRs were dizziness and somnolence but all were mild.No statistical changes in laboratory tests,such as serum glucose,lipids,electrolyte,ALT,bilirubin,creatinine and ECG,were observed.CONCLUSION:Carvedilol is an effective and well tolerated agent for treatment of mild to moderate essential hypertension.